{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T10:55:05Z","timestamp":1772967305197,"version":"3.50.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2016,7,8]],"date-time":"2016-07-08T00:00:00Z","timestamp":1467936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"National Oncologic PET Registry"},{"name":"World Molecular Imaging Society"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction.<\/jats:title>\n                  <jats:p>We assessed the impact of [18F]-fluorodeoxyglucose (FDG)-positron emission tomography (PET) on intended management of patients in the National Oncologic PET Registry (NOPR) for three different diagnostic indications: (a) determining whether a suspicious lesion is cancer (Dx), (b) detecting an unknown primary tumor site when there is confirmed or strongly suspected metastatic disease (cancer of unknown primary origin [CUP]), and (c) detecting a primary tumor site when there is a presumed paraneoplastic syndrome (PNS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods.<\/jats:title>\n                  <jats:p>We reviewed a sample of randomly selected reports of NOPR subjects who underwent PET for Dx and CUP and all reports for PNS to find subjects for analysis. For these studies, we evaluated the impact of PET on referring physicians\u2019 intended management, based on their management plans reported before and after PET.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>Intended management was changed more frequently in the CUP group (43.1%) than in the Dx (23.9%) and PNS (25.4%) groups (CUP vs. Dx, p &amp;lt; .0001; PNS vs. Dx, p &amp;lt; .0001; CUP vs. PNS, p &amp;lt; .0002). Referring physicians reported that, in light of PET results, they were able to avoid further testing in approximately three-fourths of patients (71.8%\u201374.6%). At the time when the post-PET forms were completed, biopsies of suspicious sites had been performed in 21.2%, 32.4%, and 23.2%, respectively, of Dx, CUP, and PNS cases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>Our analysis of NOPR data shows that PET appears to have a substantial impact on intended management when used for three common diagnostic indications.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2015-0364","type":"journal-article","created":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T07:22:14Z","timestamp":1468308134000},"page":"1079-1084","source":"Crossref","is-referenced-by-count":12,"title":["Impact on Patient Management of [18F]-Fluorodeoxyglucose-Positron Emission Tomography (PET) Used for Cancer Diagnosis: Analysis of Data From the National Oncologic PET Registry"],"prefix":"10.1093","volume":"21","author":[{"given":"Rathan M.","family":"Subramaniam","sequence":"first","affiliation":[{"name":"Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"},{"name":"University of Texas Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony F.","family":"Shields","sequence":"additional","affiliation":[{"name":"Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archana","family":"Sachedina","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"Hanna","sequence":"additional","affiliation":[{"name":"Center for Statistical Sciences, Brown University, Providence, Rhode Island, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenghai","family":"Duan","sequence":"additional","affiliation":[{"name":"Center for Statistical Sciences, Brown University, Providence, Rhode Island, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry A.","family":"Siegel","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA"},{"name":"Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce E.","family":"Hillner","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and the Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,7,8]]},"reference":[{"key":"2021122309533962900_B1","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.1998.16.3.1075","article-title":"Prospective investigation of positron emission tomography in lung nodules","volume":"16","author":"Lowe","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122309533962900_B2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1183\/09031936.96.09030410","article-title":"Evaluation of the solitary pulmonary nodule by positron emission tomography imaging","volume":"9","author":"Bury","year":"1996","journal-title":"Eur Respir J"},{"key":"2021122309533962900_B3","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s00259-001-0736-7","article-title":"FDG-PET as a \u201cmetabolic biopsy\u201d tool in non-lung lesions with indeterminate biopsy","volume":"29","author":"Beggs","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2021122309533962900_B4","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1007\/s002590100563","article-title":"FDG-PET as a \u201cmetabolic biopsy\u201d tool in thoracic lesions with indeterminate biopsy","volume":"28","author":"Hain","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"2021122309533962900_B5","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/hed.21566","article-title":"Clinical utility of PET\/CT in the evaluation of head and neck squamous cell carcinoma with an unknown primary: A prospective clinical trial","volume":"33","author":"Rudmik","year":"2011","journal-title":"Head Neck"},{"key":"2021122309533962900_B6","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/hed.20734","article-title":"Prospective study of 18FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor. Results from the DAHANCA-13 study","volume":"30","author":"Johansen","year":"2008","journal-title":"Head Neck"},{"key":"2021122309533962900_B7","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1634\/theoncologist.2010-0189","article-title":"18F-FDG PET\/CT as a diagnostic tool in patients with extracervical carcinoma of unknown primary site: A literature review","volume":"16","author":"Moller","year":"2011","journal-title":"The Oncologist"},{"key":"2021122309533962900_B8","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1634\/theoncologist.2011-0449","article-title":"A prospective comparison of 18F-FDG PET\/CT and CT as diagnostic tools to identify the primary tumor site in patients with extracervical carcinoma of unknown primary site","volume":"17","author":"M\u00f8ller","year":"2012","journal-title":"The Oncologist"},{"key":"2021122309533962900_B9","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1001\/archneurol.2009.336","article-title":"Positron emission tomography-computed tomography in paraneoplastic neurologic disorders: Systematic analysis and review","volume":"67","author":"McKeon","year":"2010","journal-title":"Arch Neurol"},{"key":"2021122309533962900_B10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1468-1331.2010.03220.x","article-title":"Screening for tumours in paraneoplastic syndromes: Report of an EFNS task force","volume":"18","author":"Titulaer","year":"2011","journal-title":"Eur J Neurol"},{"key":"2021122309533962900_B11","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0025-6196(11)60768-4","article-title":"Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: Value of positron emission tomography in diagnosis","volume":"83","author":"Patel","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"2021122309533962900_B12","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.2967\/jnumed.107.043687","article-title":"The National Oncologic PET Registry (NOPR): Design and analysis plan","volume":"48","author":"Hillner","year":"2007","journal-title":"J Nucl Med"},{"key":"2021122309533962900_B13","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1200\/JCO.2007.14.5631","article-title":"Impact of positron emission tomography\/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: Initial results from the National Oncologic PET Registry","volume":"26","author":"Hillner","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122309533962900_B14","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.2967\/jnumed.108.056713","article-title":"Relationship between cancer type and impact of PET and PET\/CT on intended management: Findings of the National Oncologic PET Registry","volume":"49","author":"Hillner","year":"2008","journal-title":"J Nucl Med"},{"key":"2021122309533962900_B15","doi-asserted-by":"crossref","first-page":"831","DOI":"10.2967\/jnumed.112.103911","article-title":"Impact of 18F-FDG PET used after initial treatment of cancer: Comparison of the National Oncologic PET Registry 2006 and 2009 cohorts","volume":"53","author":"Hillner","year":"2012","journal-title":"J Nucl Med"},{"key":"2021122309533962900_B16","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2967\/jnumed.109.066399","article-title":"PET and PET\/CT reports: Observations from the National Oncologic PET Registry","volume":"51","author":"Coleman","year":"2010","journal-title":"J Nucl Med"},{"key":"2021122309533962900_B17","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.285.7.914","article-title":"Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: A meta-analysis","volume":"285","author":"Gould","year":"2001","journal-title":"JAMA"},{"key":"2021122309533962900_B18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.5694\/j.1326-5377.2001.tb143587.x","article-title":"Positron emission tomography in pulmonary masses where tissue diagnosis is unhelpful or not possible","volume":"175","author":"Pitman","year":"2001","journal-title":"Med J Aust"},{"key":"2021122309533962900_B19","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/j.1365-2036.2004.02266.x","article-title":"Meta-analysis: The detection of pancreatic malignancy with positron emission tomography","volume":"20","author":"Orlando","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"2021122309533962900_B20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ygyno.2006.11.022","article-title":"The diagnostic value of PET\/CT for primary ovarian cancer\u2013a prospective study","volume":"105","author":"Risum","year":"2007","journal-title":"Gynecol Oncol"},{"key":"2021122309533962900_B21","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1007\/s11547-006-0112-6","article-title":"18F-FDG PET\/CT in the assessment of carcinoma of unknown primary origin","volume":"111","author":"Ambrosini","year":"2006","journal-title":"Radiol Med (Torino)"},{"key":"2021122309533962900_B22","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1148\/radiol.2341031554","article-title":"Unknown primary tumors: Detection with dual-modality PET\/CT\u2013initial experience","volume":"234","author":"Gutzeit","year":"2005","journal-title":"Radiology"},{"key":"2021122309533962900_B23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/MNM.0b013e328332b340","article-title":"The value of 18F-fluorodeoxyglucose positron emission tomography\/computed tomography in carcinoma of an unknown primary: Diagnosis and follow-up","volume":"31","author":"Yapar","year":"2010","journal-title":"Nucl Med Commun"},{"key":"2021122309533962900_B24","first-page":"15","article-title":"Role of whole body positron emission tomography\/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site","volume":"50","author":"Pelosi","year":"2006","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"2021122309533962900_B25","volume-title":"NCCN clinical practice guidelines oncology. Occult primary (version 2.2007)","author":"Ettinger","year":"2007"},{"key":"2021122309533962900_B26","article-title":"NCCN clinical practice guidelines oncology. Occult primary (version 1.2015)","volume-title":"National Comprehensive Cancer Network","author":"Ettinger","year":"2015"},{"key":"2021122309533962900_B27","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1600-0404.2008.01089.x","article-title":"PET scan in clinically suspected paraneoplastic neurological syndromes: A 6-year prospective study in a regional neuroscience unit","volume":"119","author":"Hadjivassiliou","year":"2009","journal-title":"Acta Neurol Scand"},{"key":"2021122309533962900_B28","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1097\/MNM.0b013e3283550237","article-title":"18F-FDG PET-CT in the evaluation of paraneoplastic syndromes: Experience at a regional oncology centre","volume":"33","author":"Vaidyanathan","year":"2012","journal-title":"Nucl Med Commun"},{"key":"2021122309533962900_B29","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1093\/brain\/awh247","article-title":"FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes","volume":"127","author":"Younes-Mhenni","year":"2004","journal-title":"Brain"},{"key":"2021122309533962900_B30","first-page":"85","article-title":"Paraneoplastic syndromes: Detection of malignant tumors using [(18)F]FDG-PET","volume":"47","author":"Berner","year":"2003","journal-title":"Q J Nucl Med"},{"key":"2021122309533962900_B31","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1093\/brain\/124.11.2223","article-title":"The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders","volume":"124","author":"Rees","year":"2001","journal-title":"Brain"},{"key":"2021122309533962900_B32","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1007\/s00259-013-2372-4","article-title":"Detection of underlying malignancy in patients with paraneoplastic neurological syndromes: Comparison of 18F-FDG PET\/CT and contrast-enhanced CT","volume":"40","author":"Schramm","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2021122309533962900_B33","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1007\/s00259-015-3126-2","article-title":"Clinical value of FDG-PET\/CT in suspected paraneoplastic syndromes: A retrospective analysis of 137 patients","volume":"42","author":"Kristensen","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2015-0364","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2015-0364","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/9\/1079\/41875469\/oncolo_21_9_1079.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/9\/1079\/41875469\/oncolo_21_9_1079.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T04:31:54Z","timestamp":1640320314000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/21\/9\/1079\/6401485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,8]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2016,7,8]]},"published-print":{"date-parts":[[2016,9,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2015-0364","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,9,1]]},"published":{"date-parts":[[2016,7,8]]}}}